선택지 정리됨
중피종: 국가별 치료 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨고형암최종 확인 2026.06
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy[1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.
European Union
- Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy[2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.
United Kingdom
- Nivolumab (Opdivo) with ipilimumab (Yervoy)[3]ApprovedNo biomarker requirement stated in fetched NICE TA818 recommendation; Untreated unresectable malignant pleural mesothelioma in adults. · NICE recommendation is conditional on ECOG performance status and commercial arrangement. Devolved nation implementation and local pathway details may vary. Confidence/conflicts: High for NICE recommendation in specified population; local implementation still needs care-team confirmation.
- Pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy[4]ApprovedNo biomarker requirement stated in fetched NICE TA1125 source; Untreated unresectable advanced malignant pleural mesothelioma in adults. · This is not a positive NICE recommendation. It does not establish routine NHS funding; local decision-making may apply if organisations consider the regimen. Confidence/conflicts: High for no NICE recommendation; conflict with U.S. FDA and EU EMA approvals is jurisdiction/access-specific.
출처
- U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- NICE — technology appraisal recommendation · technology appraisal recommendation
- NICE — terminated technology appraisal advice · terminated technology appraisal advice
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 일부 선택지는 신속·조건부 승인 상태로, 적응증이 축소되거나 철회될 수 있습니다. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026.06.
승인된 치료 너머
임상시험 및 신흥 선택지
환자가 거주하는 국가에서 아직 승인된 표준 치료가 아닌 선택지입니다 — 연구, 임상시험, 허가 외 사용, 담당 종양내과 의사가 먼저 언급하지 않을 수 있는 초기 근거입니다. 각 항목은 근거의 강도에 따라 구분됩니다. 여기에 실린 항목은 조사하고 의료진과 상의할 정보일 뿐, 효과가 입증되었거나 안전하거나 현재 이용 가능하다는 의미가 아닙니다. 임상 세부 내용은 영문이 정본입니다.
임상시험 진행 중
- Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiation임상시험임상시험Reported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
- Pembrolizumab with cisplatin and pemetrexed; nivolumab (Opdivo) with ipilimumab (Yervoy); rinatabart sesutecan with possible carboplatin/bevacizumab/pembrolizumab combination context임상시험 · NCT04153565임상시험Trial only (registry)Japan · No biomarker required by fetched Japan registry records; Advanced MPM; unresectable advanced/recurrent MPM; advanced solid tumor study including mesothelioma. · Registry listing does not establish PMDA approval, reimbursement, routine access, current enrollment for completed studies, or individual eligibility. Confidence/conflicts: High for Japan registry-listed studies; approval/access remains unverified. ClinicalTrials.gov — clinical-trial registry
- Volrustomig; anetumab ravtansine (BAY94-9343) versus vinorelbine; tulmimetostat; KFA115 with pembrolizumab; NGM707 with pembrolizumab임상시험 · NCT06535607임상시험Trial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced/metastatic solid tumor including mesothelioma; second-line MPM for anetumab ravtansine record; unresectable pleural mesothelioma sub-study for volrustomig. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are broader solid-tumor baskets rather than mesothelioma-only studies. Confidence/conflicts: Medium-high for South Korea trial landscape; local approval status not established. ClinicalTrials.gov — clinical-trial registry
- Sintilimab plus anlotinib plus pemetrexed/cisplatin; PM8002 with pemetrexed and platinum chemotherapy; alphaPD1-MSLN-CAR T cells; iparomlimab plus tovorilimab plus bevacizumab/pemetrexed/cisplatin; nivolumab plus ipilimumab versus pemetrexed/platinum; rinatabart sesutecan임상시험 · NCT05188859임상시험Trial only (registry)China · MSLN-positive required for alphaPD1-MSLN-CAR T-cell study; otherwise no biomarker requirement stated in fetched China registry records; First-line malignant pleural mesothelioma; unresectable pleural mesothelioma; MSLN-positive advanced solid tumors including mesothelioma; advanced solid tumors including mesothelioma. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some records are not-yet-recruiting or unknown-status. Confidence/conflicts: High for China registry-listed investigational options; regulatory access unverified. ClinicalTrials.gov — clinical-trial registry
- PIPAC registry context; cosibelimab; NGR-hTNF maintenance plus best supportive care; nivolumab/ipilimumab versus pemetrexed/platinum; anetumab ravtansine versus vinorelbine; rAd-IFN with celecoxib and gemcitabine; tremelimumab; nintedanib with pemetrexed/cisplatin임상시험 · NCT03210298임상시험Trial only (registry)Russia · No biomarker requirement stated in fetched Russia registry records; Advanced MPM maintenance; first-line unresectable pleural mesothelioma; second-line MPM; unresectable pleural/peritoneal mesothelioma; registry context for PIPAC. · Registry records do not establish Russian regulatory approval, reimbursement, routine access, current enrollment, or individual eligibility. Some records are completed, terminated, unknown status, or registry rather than interventional treatment access. Confidence/conflicts: Medium-high for Russia registry landscape; current routine availability unverified. ClinicalTrials.gov — clinical-trial registry
- Cosibelimab (CK-301)임상시험 · NCT03212404임상시험Trial only (registry)Thailand · No biomarker requirement stated in fetched registry record; Advanced cancers including advanced malignant mesothelioma. · Registry listing does not establish Thai FDA approval, reimbursement, routine access, active enrollment at every site, or individual eligibility. Confidence/conflicts: Medium-high for Thailand registry listing; current access and local approval unverified. ClinicalTrials.gov — clinical-trial registry
임상시험이나 초기 보고에 실렸다는 것은 해당 선택지가 연구되고 있다는 의미일 뿐, 효과가 있거나 특정 환자에게 안전하거나 현재 등록 가능하다는 뜻은 아닙니다. 어떤 선택지가 적합한지는 담당 종양내과 팀과 임상시험 팀이 함께 상의할 문제입니다. 최종 확인 2026.06.
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- Is the disease localized, advanced, recurrent, pleural, peritoneal, or another site?
- Is the goal disease-directed systemic therapy, surgery, symptom relief, or clinical-trial participation?
- Which symptoms need supportive management now, such as effusion, pain, or breathing issues?
- Is the MPM unresectable advanced or metastatic and untreated with systemic therapy in that setting?